Symposier - Does Treatment with Everolimus + Octreotide LAR Affect 5-HIAA Levels in Patients with Advanced NeuroEndocrine Tumors
Links shared publicly online about this topic.
- 283total visits
Symposier - Does Treatment with Everolimus + Octreotide LAR Affect 5-HIAA Levels in Patients with Advanced NeuroEndocrine Tumors
Uploaded and shared in Youtube by: OncUViewTV --" Dr. Eric Baudin discusses results from the RADIANT 2 study as part of a continuing series, Headline News in NETS 2011. This program is supported by an un-restricted educational grant from Novartis Oncology and intended for non-US audiences only.
View full resource at symposier.com
Tags: Kidney Cancer Medication, Afinitor, Novartis, Oncology, News, Education
Most Recently Shared on March 17, 2012 at 5:21 pm By:
Does Treatment with Everolimus + Octreotide LAR Affect 5-HIAA Levels in Patients with Advanced NeuroEndocrine Tumors. http://t.co/gyU7FtsT
Advertisement
